Ranibizumab’s Impact on Diabetic Retinopathy Assessed
Treatment with ranibizumab significantly improved diabetic retinopathy (DR) in patients at high risk for DR-related vision loss, regardless of baseline diabetic macular edema (DME) status, according to results of three randomized phase 3 studies involving more than 1,100 individuals. The findings were presented by Avanti Ghanekar, OD, principal medical science liaison at Genentech, during the American Diabetes Association’s 78th Scientific Sessions.
Participants in the RIDE/RISE trials with DME (n=759) received ranibizumab either 0.3 or 0.5 mg or sham treatment. Meanwhile, in the Protocol S study, patients with and without DME (n=394) received either pan-retinal photocoagulation or ranibizumab 0.5 mg as needed after 3 monthly treatments. Investigators looked at outcomes at month 24.
- ~3 in every 10 patients in both arms had high-risk nonproliferative DR at baseline.
- Within that subgroup, ~8 in every 10 of ranibizumab-treated patients achieved ≥2-step DR improvement, vs 12% of those who received sham treatment.
- The improvement seen in the subgroups who received ranibizumab was more than twice as high as that seen in the overall study population.
In Protocol S:
- 87% of eyes had proliferative DR and 22% had DME at baseline.
- Ranibizumab treatment resulted in ≥2-step DR improvement in 59% of eyes with baseline DME and 39% of those without such at baseline.
Ghanekar A. Ranibizumab-induced diabetic retinopathy improvement: Results from patients at high risk for vision loss in RIDE/RISE and Protocol S. Talk presented at: ADA 78th Scientific Sessions; June 22-26, 2018; Orlando.
Grandin Library Building
Six Leigh Street
Clinton, New Jersey 08809